116 related articles for article (PubMed ID: 38908102)
1. Novel dihydropyrimidines as promising EGFR & HER2 inhibitors: Insights from experimental and computational studies.
Faizan S; Wali AF; Talath S; Rehman MU; Sivamani Y; Nilugal KC; Shivangere NB; Attia SM; Nadeem A; Elayaperumal S; Kumar BRP
Eur J Med Chem; 2024 Jun; 275():116607. PubMed ID: 38908102
[TBL] [Abstract][Full Text] [Related]
2. Design, parallel synthesis of Biginelli 1,4-dihydropyrimidines using PTSA as a catalyst, evaluation of anticancer activity and structure activity relationships via 3D QSAR studies.
Faizan S; Prashantha Kumar BR; Lalitha Naishima N; Ashok T; Justin A; Vijay Kumar M; Bistuvalli Chandrashekarappa R; Manjunathaiah Raghavendra N; Kabadi P; Adhikary L
Bioorg Chem; 2021 Dec; 117():105462. PubMed ID: 34753059
[TBL] [Abstract][Full Text] [Related]
3. Novel Biginelli dihydropyrimidines with potential anticancer activity: a parallel synthesis and CoMSIA study.
Prashantha Kumar BR; Sankar G; Nasir Baig RB; Chandrashekaran S
Eur J Med Chem; 2009 Oct; 44(10):4192-8. PubMed ID: 19525040
[TBL] [Abstract][Full Text] [Related]
4. Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancer
Faizan S; Talath S; Wali AF; Hani U; Haider N; Mandal SP; Kumar BRP
RSC Adv; 2024 Apr; 14(16):11368-11387. PubMed ID: 38595721
[TBL] [Abstract][Full Text] [Related]
5. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
Raghunath Khedkar N; Sindkhedkar M; Joseph A
Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
[TBL] [Abstract][Full Text] [Related]
6. New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
Fakhry MM; Mattar AA; Alsulaimany M; Al-Olayan EM; Al-Rashood ST; Abdel-Aziz HA
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959874
[No Abstract] [Full Text] [Related]
7. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives.
Elkamhawy A; Son S; Lee HY; El-Maghrabey MH; Hamd MAE; Alshammari SO; Abdelhameed AA; Alshammari QA; Abdeen A; Ibrahim SF; Mahdi WA; Alshehri S; Alnajjar R; Choi WJ; Al-Karmalawy AA; Lee K
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678540
[TBL] [Abstract][Full Text] [Related]
9. Computational Studies of bis-2-Oxoindoline Succinohydrazides and their In Vitro Cytotoxicity.
Jarapula R; Badavath VN; Rekulapally S; Manda S
Curr Comput Aided Drug Des; 2020; 16(3):270-280. PubMed ID: 30652647
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity, anti-angiogenic, anti-tumor and molecular docking studies on phytochemicals isolated from Polygonum hydropiper L.
Mahnashi MH; Alqahtani YS; Alyami BA; Alqarni AO; Ullah F; Wadood A; Sadiq A; Shareef A; Ayaz M
BMC Complement Med Ther; 2021 Sep; 21(1):239. PubMed ID: 34560864
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
13. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
Sabry MA; Ghaly MA; Maarouf AR; El-Subbagh HI
Eur J Med Chem; 2022 Nov; 241():114661. PubMed ID: 35964425
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors.
Olgen S; Biltekin Kaleli SN; Karaca BT; Demirel UU; Bristow HK
Curr Med Chem; 2023 Jun; ():. PubMed ID: 37365789
[TBL] [Abstract][Full Text] [Related]
15. Rational Design, Synthesis and Biological Evaluation of Novel Pyrazoline-Based Antiproliferative Agents in MCF-7 Cancer Cells.
Fakhry MM; Mahmoud K; Nafie MS; Noor AO; Hareeri RH; Salama I; Kishk SM
Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297358
[TBL] [Abstract][Full Text] [Related]
16. Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR
Aljohani AKB; El-Adl K; Almohaywi B; Alatawi OM; Alsulaimany M; El-Morsy A; Almadani SA; Alharbi HY; Aljohani MS; Abdulhaleem M FA; Osman HEM; Mohamady S
RSC Adv; 2024 Mar; 14(12):7964-7980. PubMed ID: 38454937
[TBL] [Abstract][Full Text] [Related]
17. Discovery and evaluation of cytisine N-isoflavones as novel EGFR/HER2 dual inhibitors.
Wang Y; Yin X; Chen L; Yin Z; Zuo Z
Bioorg Chem; 2022 Oct; 127():105868. PubMed ID: 35816874
[TBL] [Abstract][Full Text] [Related]
18. New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: Synthesis, anticancer evaluation, and molecular modeling studies.
Hawas SS; El-Sayed SM; Elzahhar PA; Moustafa MA
Bioorg Chem; 2023 Dec; 141():106874. PubMed ID: 37769524
[TBL] [Abstract][Full Text] [Related]
19. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
20. Quinazolin-4(3
Mirgany TO; Abdalla AN; Arifuzzaman M; Motiur Rahman AFM; Al-Salem HS
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2055-2067. PubMed ID: 34551654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
